Rybelsus Tablets (Semaglutide) – Product Information
Rybelsus (Semaglutide 14mg tablets) is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Semaglutide increases glucose-dependent insulin release, decreases glucagon secretion, and slows gastric emptying.
Semaglutide is used for weight loss in specific patients, and also to lower blood sugar levels, and to reduce the risk of major cardiovascular events such as heart attack or stroke in certain patients.
We also stock Glycomet (Metformin Tablets) and Exermet XR ((Metformin SR) which are used to treat type 2 diabetes mellitus in adults, when diet and exercise alone does not result in adequate control of blood glucose levels.
Name of Drug
Rybelsus . Semaglutide is also available as Rybelsus 3 mg and 7 mg tablets.
Manufacturer of Rybelsus Tablets (Semaglutide Tablets)
Novo Nordisk, Denmark and distributed by Abbott India Limited
Website: www.novonordisk.com
Active Pharmaceutical Ingredient
The active pharmaceutical ingredients contained in Rybelsus tablets is Semaglutide.
Each Rybelsus tablet contains 14 mg of Semaglutide.
Mechanism of Action
Rybelsus works by mimicking the effects of GLP-1, a naturally occurring incretin hormone that is usually released following a meal.Semaglutide improves the efficiency of incretin function by activating GLP-1 receptors.
Rybelsus stimulates the secretion of insulin following food, reduces the amount of glucose produced by the liver, and helps to make you feel full after food.
This medicine acts by various mechanisms like augmented insulin secretion (glucose-dependent), inhibition of glucagon release and suppressed hepatic gluconeogenesis; thereby reducing both fasting as well as postprandial glucose.
Uses of Rybelsus Tablets (Semaglutide)
Rybelsus 14mg tablets (Semaglutide) is an oral medicine that is used to improve blood sugar control in adults over the age of 18 with type 2 diabetes. It may be prescribed as first-line therapy in addition to diet and exercise or in addition to other medications typically used for type 2 diabetes.
Semaglutide, the active ingredient in Rybelsus tablets is used for weight loss in specific patients, and also to lower blood sugar levels, and to reduce the risk of major cardiovascular events such as heart attack or stroke in certain patients.
Dosage
The starting dose of Rybelsus tablets (Semaglutide) for adult patients 18 years and over is 3 mg once daily for one month. After one month, the dose should be increased to a maintenance dose of 7 mg once daily.
After at least one month with a dose of 7 mg once daily, the dose can be increased to a maintenance dose of 14 mg once daily to further improve glycaemic control.
Can You Cut Rybelsus Tablets In Half
Rybelsus 14 mg tablets should not be split, crushed or chewed, as it is not known whether this impacts absorption of semaglutide.
Missed Dosage Instructions for Rybelsus Tablets
If you miss a daily dose of Rybelsus, skip the missed dose and continue with your usual dosing schedule the next day.
Do not take two doses of Rybelsus at one time to make up for the missed dose.
Contraindications
Rybelsus tablets are contraindicated in persons with a hypersensitivity (allergy) to Semaglutide or any of the other ingredients of this medicine.
They are also contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2
Storage Instructions for Rybelsus Tablets
Store at 68°F to 77°F (20°C to 25°C); excursions permitted to 59°F to 86°F (15°C to 30°C). Store and dispense in the original bottle.
Store tablet in the original bottle until use to protect tablets from moisture. Store product in a dry place away from moisture.
Warnings and Precautions to be taken when using Semaglutide Tablets
Before using Semaglutide tablets (Rybelsus 14mg tablets) please inform your doctor about all the medicines that you take including no prescription medications, over the counter medicines and herbal remedies.
Pancreatitis: Has been reported in clinical trials. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed.
Diabetic Retinopathy Complications: Has been reported in a cardiovascular outcomes trial with semaglutide injection. Patients with a history of diabetic retinopathy should be monitored.
Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia.
Reducing dose of insulin secretagogue or insulin may be necessary.
Acute Kidney Injury: Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions.
Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue Rybelsus if suspected and promptly seek medical advice
Side Effects of Semaglutide Tablets
The possible Side Effects of Semaglutide tablets (Rybelsus 14mg tablets) reported in 5% or greater of patients treated with
this medicine are: nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation.
Drug Interactions
The drug Interactions are given below:
- Rybelsus stimulates insulin release in the presence of elevated blood glucose concentrations. Patients receiving RYBELSUS in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia.
- Rybelsus causes a delay of gastric emptying, and thereby has the potential to impact the absorption of other oral medications. Levothyroxine exposure was increased 33% when administered with Rybelsus in a drug interaction study.
Overdosage
In the event of overdose, appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms.
A prolonged period of observation and treatment for these symptoms may be necessary, taking into account the long half-life of RYBELSUS of approximately 1 week.
Semaglutide During Pregnancy
Available data with Semaglutide tablets (Rybelsus 14mg tablets) use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes.
There are clinical considerations regarding the risks of poorly controlled diabetes in pregnancy. Based on animal reproduction studies, there may be potential risks to the fetus from exposure to Rybelsus during pregnancy.
Rybelsus should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Discontinue Rybelsus in women at least 2 months before a planned pregnancy due to the long washout period for Semaglutide.
It is not known whether is excreted in human milk. There are no data on the presence of Semaglutide in human milk, the effects on the breastfed infant, or the effects on milk production. Semaglutide was present in the milk of lactating rats. Because of the unknown potential for serious adverse reactions in the breastfed infant breastfeeding is not recommended during treatment with Rybelsus.
Buy Rybelsus 14mg Tablets (Semaglutide Tablets) Online
You can buy Semaglutide tablets online at a cheap price from the Swiss Pharmacy. Rybelsus 14mg pills, manufactured by Novo Nordisk, Denmark and distributed by Abbott India Limited are priced at only $14.94 per unit if you place an order for 120 tablets.
